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ABSTRACT 
Epithelial tumour or carcinoma is the most common cause of death in individual 
with cancer worldwide. Molecular basis of epithelial tumor is poorly 
understood. To elucidate the mechanism behind the abstractness of epithelial 
tumor, “Molecular Signature” is the more accurate and effective than possible 
standard approach. Microarray data analysis has made it possible to obtain 
molecular snapshot of genes of an organism at various disease state and 
experimental conditions. In this study, we discussed the uncovering of 
molecular signature from epithelial tumors (Brain, Stomach, Cervical cancer) 
on the basis of relative fold change and potential biomarker ability in cancer. To 
explore the molecular signature in epithelial tumor, we compared the gene 
expression profile of brain, stomach, cervical cancer. From microarray analysis 
we found 201 exclusive set of common genes in tumors of epithelial origin and 
from 201 genes, we are able to identify 10 genes that can be used as molecular 
signature for all types of cancer which has epithelial origin. Selected two genes 
(SERPINA3, SH3GL3) were experimentally validated by qRT-PCR in HeLa 
cell line. qRT-PCR established that these two  genes are showing their up 
regulation with respect to Beta-Actin, which is a housekeeping gene. The 
identification of molecular signature has promising application for accurate 
detection, promote early diagnosis and screening of cancer. 
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INTRODUCTION 
Just as an individual’s signature is unique and identifies him or her, the gene 
activity/expression profile of a cell or tissue can be a unique identifying molecular ‘signature’ 
for that cell or tissue. Molecular signatures or gene-expression signatures are one of the most 
significant translational developments of recent years. Since 1998, potential of molecular 
signatures has been established (www.nyuinformatics.org). Molecular signature is defined 
as a set of biomolecular features (e.g. DNA sequence, DNA copy number, RNA, protein, and 
metabolite expression) together with a predefined computational procedure that applies those 
features to predict a phenotype of clinical interest on a previously unseen patient sample 
(Sung J et al., 2012). Thus the unique pattern of gene expression for a given cell or tissue is 
referred to as its molecular signature. 
 
As a structural and functional unit of organisms, normal cells are carefully programmed to 
participate in constructing the diverse tissues that make possible organism survival. When 
cells in a part of the body start to grow abnormally and uncontrollably, they are called 
tumour. There are several kinds of tumour. A tumor can be benign or malignant. The cells of 
benign tumours are close to normal in appearance and are not considered cancerous. They do 
not have the potential of being dangerous and grow slowly and do not invade nearby tissues 
or spread to other parts of the body. On the other hand a malignant tumour is cancerous and 
can spread beyond the original tumor to other parts of the body. They have a quite different 
and more focused agenda. They appear to be motivated by only one consideration: making 
more copies of themselves (Ames B. N, 1983). Cells, in an initially formed primary 
malignant tumour may travel to other parts of the body and seed new tumour colonies at 
distant sites in the body, where they begin to grow and form new tumours. This process is 
called metastasis. Angiogenesis is a key process in tumor growth and spread in which 
tumours provoke the growth of new blood vessels to the tumor from pre-existing vessels; 
these new blood vessels provide the tumor with oxygen and nutrients, allowing these cells to 
grow, invade nearby tissue and spread to other parts of the body . 
Cancers are classified according to the embryonic origin of tissues and their histological 
structure. The international standard for the classification and nomenclature of histologies is 
the International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3). From the 
histological point of view there are hundreds of different cancers, which are grouped into 4 
major categories: epithelial tumours (carcinomas), connective tumours (sarcomas), 
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hematopoietic tissue tumours and nervous system tumours. Of these human, carcinomas, 
derived from epithelial tissues account for 80 to 90 percent of all cancer and sarcomas being 
relatively rare malignant tumours comprise less than 10% of all cancers (Jemal et al., 2003).  
Carcinoma includes cancers of the breast, prostate, lung, pancreas and colon cancer. They 
have a number of subtypes which include adenocarcinoma, basal cell carcinoma, squamous 
cell carcinoma, and transitional cell carcinoma. Connective tissue tumors or sarcomas are 
further classified on the basis of the site of the tumor: bone or soft tissue (Lahat et al., 2008). 
Of these, soft tissue sarcoma (STS) is the collective term used for malignancies arising in 
muscles, fat, vessels and fibrous tissues (WHO classification). Nervous system cancer 
includes cancers of the different types of cells of the nervous system like glial cells, 
neuroepithelial cells, etc. Hematopoietic tissue tumours include leukemia, lymphoma and 
other related disorders. Here the cancer arise from hematopoietic (blood forming) cells that 
leave the bone marrow and tend to mature in lymph nodes or blood.  
Gene expression signatures can be important both for diagnostic purpose and for providing 
information about the biological system underlying certain conditions by certain highlighting 
genes, which are both related to those conditions. Molecular signatures are often used to 
model patient’s clinically relevant information like prognosis, survival time, etc, as a function 
of the gene expression data (Mehrabian et al., 2005; Hur et al., 2011). Individual genes used 
as a function of the gene expression data, are known as the signature components or 
metagenes. Each signature component show strong co-expression in different cancerous 
conditions. In cancer, use of signature is able to build a successful model, and able to predict 
the probability of developing stage of a metastasis.  
 
Recent technological developments have made it possible to obtain high-resolution molecular 
snapshots of organisms, tissues, and even individual cells at various disease states and 
experimental conditions. Techniques in genomics, like DNA microarray are one of the most 
important development which are extremely useful for understanding gene functions and 
interactions. Gene expression profiling using microarray technology is one of the essential 
tools to monitor genome wide expression levels of genes in a given organism. Molecular 
signatures or gene-expression signatures are a key feature in many studies, and the use of 
microarray data for its generation is valuable in different disease diagnosis (Alizadeh et al. 
2000; Pomeroy et al. 2002). Usually, microarray is a glass slide on to which DNA molecules 
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are fixed in an orderly manner at specific locations called spots. The most common tools used 
to carry out these measurements include complementary DNA microarrays (Schena, 1995), 
oligonucleotide microarrays (Lockhart et al. 1996) or serial analysis of gene expression 
(SAGE) (Velculescu et al. 1996). Microarrays may be used to measure gene expression in 
many ways, but one of the most common applications is to compare expression of a set of 
genes from a cell maintained in a particular disease condition to the same set of genes from a 
reference cell maintained under normal conditions. Significance of microarray data in basic 
research and target discovery is finding genes expressed in significantly different patterns 
across samples. It also includes biomarker determination to find genes that correlate with and 
presage disease progression. Generally microarray datas are available in Gene Expression 
Omnibus (GEO) Database of National Center for Biotechnology Information (NCBI). GEO 
contains large amount of array- and sequence-based data which are freely available for 
experimental as well as academic use. Many softwares are used to assists microarray data 
analysis like Gene spring, R, Bioconductor, dChip, Multi expression Viewer, MA Explorer, 
RELNET etc. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
REVIEW OF LITERATURE 
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 REVIEW OF LITERATURE 
2.1. Cancer: 
Cancer is the unregulated growth of cells resulting from gene mutations occurring due to 
various reasons.  In cancer, cells divide and grow uncontrollably, forming malignant tumors, 
and invade nearby parts of the body. The cancer may also spread to more distant parts of the 
body through the lymphatic system or blood stream.  Not all tumors are cancerous. Benign 
tumors do not grow uncontrollably, do not invade neighbouring tissues, and do not spread 
throughout the body. There are over 200 different known cancers that badly affect humans 
(Cancer Research UK, May, 2012).  In 2008, an estimated 12.7 million new cancer cases were 
diagnosed worldwide. Lung, female breast, colorectal and stomach cancers were the most 
commonly diagnosed cancers, accounting for more than 40% of all cases. An estimated 7.6 
million deaths from cancer occurred worldwide in 2008. Half of the cancer death is due to 
most common cancer like ling, stomach, liver, colorectal and female breast cancers (Cancer 
research, UK). 
 
Common elements of staging of cancer are site of cancer, tumor size and number of tumors, 
lymph node involvement, cell type and tumor grade, the presence or absence of metastasis 
(National Cancer Institute). Cancer varies by stages. There are different stages of cancer. 
Hyperplasia, where the cells still appears normal, but is dividing too rapidly. The term 
Dysplasia used when cellular abnormality is restricted to the originating tissue. And in 
Invasive cancer, Cancer that has spread beyond the layer of tissue in which it developed and is 
growing into surrounding, healthy tissues. In Metastasis cancer,  primarily formed malignant 
tumor may spread to other parts of the body and seed new tumor colonies. Invasive and 
metastasis cancer are looks like same, in both cases cells are invaded to the surrounding tissue 
and has potential to travel through the lymphatic system (Carlson et al., 2009). Metastasis is 
the principal event leading to death in individuals with cancer, yet its molecular basis is poorly 
understood (Sridher et al., 2002).  
 
2.2. Classification of cancers: 
According to the International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3), 
tumors are classified based upon the morphology and topography of the neoplasm into 4 
catagoies. These are epithelial cancer (carcinoma), connective tissue or mesenchymal cancer 
(sarcoma), Nervous system cancer, Hematopoietic cancer (leukemia and lymphoma).  
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Carcinoma: Carcinoma is one form of cancer that composed of cells, have developed the 
cytological appearance, histological architecture or molecular characteristics of epithelial cells 
(Berman, 2004).   Epithelial cancer or carcinoma is most common type of cancer that occurring 
in humans. It begins in a tissue that lines the inner or outer surface of the body organ. 
Generally that has ectodermal or endodermal origin during embryogenesis. The majority of 
cancers in industrialized countries are solid tumors derived from epithelial tissues such as 
carcinomas of the breast, lung, gastrointestinal tract, and prostate (Woelfle et al., 2003). 
Usually, carcinomas have generally been classified in to various types using a combination of 
criteria including histology, Adenocarcinoma, Basal cell carcinoma, Squamous cell carcinoma, 
and Transitional cell carcinoma. Frequent origin site of carcinoma is lungs, breast, prostate, 
colon, pancreas, cervical, stomach and brain.   
 
Brain Cancer (Glioblatoma): It is the most common and aggressive primary brain tumour 
that involves glial cells. Glioblastoma is a highly vascular tumor that expresses vascular 
endothelial growth factor, a key regulator of angiogenesis and tumor blood vessel permeability 
(Narita, 2013). The majority of cases (>90%) are primary glioblastomas that develop rapidly 
through de novo pathway, without clinical or histological evidence of a less malignant 
precursor lesion. Secondary glioblastomas develop through progression from low-grade 
diffusion of astrocytoma or anaplastic astrocytoma. During progression to glioblastoma, 
additional mutations accumulate, including loss of heterozygosity in 10q25-qter which is 
approximately 70% and it is the most frequent genetic alteration in both primary and secondary 
glioblastomas (Ohgaki and Kleihues, 2007).  
Stomach (Gastric) Cancer: It is hard to diagnose stomach cancer in its early stages. Most 
stomach cancer is caused by Helicobacter pylori infection. Atrophy of acid-secreting parietal 
cells (PCs) frequently occurs during infection with Helicobacter pylori. During loss of 
hyaloruinic acid receptor, CD44 labelled undifferentiated cells in gastric unit of isthmus shows 
decrease proliferation of the gastric epithelium. CD44 binds with STAT3 and inhibition of 
either CD44 or STAT3 signalling causes decrease proliferation (Khurana et al., 2013). 
Cervical cancer: Worldwide cervical cancer is the most common type of cancer in woman 
(Chepovetsky at al., 2013). It starts in the squamousal epithelium of cervix, which is the lower 
part of the uterus. All cervical cancers are caused by the infections of HPV (Human papilloma 
virus) appears to be a necessary factor in the development of almost all cases (90%) of cervical 
cancer (Walboomers et al., 1999). Infection is extremely common in young women. There are 
four major steps in cervical cancer development: infection of metaplastic epithelium at the 
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cervical transformation zone, viral persistence, progression of persistently infected epithelium 
to cervical pre-cancer, and invasion through the basement membrane of the epithelium 
(Schiffman et al., 2007). 
 Sarcoma: Connective tissue tumors or sarcomas are further classified on the basis of    the site 
of the tumor: bone or soft tissue (Lahat et al., 2008). Of these, soft tissue sarcoma (STS) is the 
collective term used for malignancies arising in muscles, fat, vessels and fibrous tissues (WHO 
classification).Sarcoma developed from transformed cell of mesenchymal origin. Liposarcoma 
arises from fat where Leiomyosarcoma arises from smooth muscle. 
Leiomyosarcoma: It is a rare malignant cancer of smooth muscle, accounts for 5-10% of 
cancers in smooth tissue muscle. It is resistant to chemotherapy and radiation and mainly found 
in any sites of the body like uterus (Arnold et al., 2012), stomach, small intestine, 
retroperitoneum (Piovanelloet al., 2007).  
            Liposarcoma: Liposarcoma is a malignant tumor that arises in fat cells of deep soft      tissue 
and accounts for approximately 20% of all mesenchymal malignancies. They are large bulky 
tumor present inside the thigh or in the retroperitoneum. 
Myxofibrosarcoma (MFS): Myxofibrosarcoma is one of the most common sarcomas in the 
extremities of elderly patients (Mentzel et al., 1996), present in trunk (12%), retroperitoneum 
or mediastinum (8%) and head (3%) (Mansoor and White, 2003). It characterised by distinct 
vascular patterns.  Myxofibrosarcoma is a connective tissue neoplasm of fibroblastic origin set 
in a myxoid matrix and has been classified by some as a myxoid variant of malignant fibrous 
histiocytoma (MFH) (Wada et al., 2000; Mansoor and White, 2003). The majority of acral 
myxofibrosarcomas are observed in the leg rather than the arm, often attributed to the fact that 
the leg contains a greater volume of connective tissue and thus has a greater chance for 
malignant development (Hollowood et al., 1995; Ninfo et al., 1998; Arenson et al., 1986) 
 
Hematopoietic cancer: Hematopoiesis gives rise to blood cells of different lineages 
throughout normal life. This cancer falls into two categories, Lymphoma and Leukemia. 
Abnormalities in this developmental program lead to blood cell diseases including lymphoma, 
when blood cancer occurs in B or T lymphocytes. Lymphocytes help to protect the body from 
various infection and disease. Abnormal lymphocytes divide faster than other normal cells. It 
develops in many parts of the body including the lymph nodes, spleen, blood and bone marrow 
(Medical News Today, 2013). 
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2.3. Microarrays Gene expression: 
Microarrays Gene expression are prominent experimental tool in functional genomics allowing 
gaining of a deeper understanding of biological processes (Schena et al., 2005). In a single 
experiment, we can measure gene expression levels for thousands of genes and even an entire 
genome (Khalid et al., 2006). 
Molecular diagnostics is a rapidly advancing field in which insights into disease mechanisms 
are being elucidated by use of new gene-based biomarkers. Some genes, proteins and some 
genetic variants are used to characterise the molecular signature of certain cancer. Microarray 
analysis helps to provide invaluable information on disease pathology, progression, resistance 
to treatment, ultimately leads to improved early diagnosis and innovative therapeutic 
approaches for cancer (Pascale et al., 2002). 
2.4. Microarray Analysis tools: 
R: R is a free software environment for statistical computing and graphics. It compiles and 
runs on a wide variety of UNIX platforms, Windows and  MacOS 
Bioconductor: Bioconductor is an open source and open development software project 
analysis of genomic data, especially microarray data. 
dChip: DNA- Chip Analyzer(dChip) is a model-based expression analysis of oligonucleotide       
arrays. It is a free software package, can be downloaded. It is also implemented in 
the Bioconductor package. 
TM4: TM4 is a free suite of software tools for microarray analysis. It consists of 4 major 
applications: Microarray Data Manager (MADAM), Spotfinder, Microarray Data Analysis 
System (MIDAS) and Multiexperimant Viewer (MeV). 
GenMAPP: Gene Map annotator and Pathway Profiler (GenMAPP) is free software for 
visualizing gene expression and proteomics data on pre-packaged and custom pathway 
(MAPPs). 
GeneSpring: GeneSpring is widely-used commercial microarray analysis software. 
Spotfire: Spotfire DecisionSite for Functional Genomics is commercial software for 
microarray analysis. 
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2.5. qRT-PCR: As we all know, the advent of Polymerase Chain Reaction (PCR) by Kary 
B. Mullis in the mid-1980s revolutionized molecular biology. At its most basic application, 
PCR can amplify a small amount of template DNA (or RNA) into large quantities in a few 
hours. This is performed by mixing the DNA with primers on either side of the DNA 
(forward and reverse), Taq polymerase (of the species Thermus aquaticus, a thermophile 
whose polymerase is able to withstand extremely high temperatures), free nucleotides 
(dNTPs for DNA, NTPs for RNA), and buffer. The temperature is then alternated between 
hot and cold to denature and reanneal the DNA, with the polymerase adding new 
complementary strands each time. In addition to the basic use of PCR, specially designed 
primers can be made to ligate two different pieces of DNA together or add a restriction site 
(Purves, et al. 2001). Recently,a new method of PCR quantification has been invented. This 
is called “real-time PCR” because it allows to viewing the increase in the amount of DNA as 
it is amplified. Several different types of real-time PCR are being marketed to the scientific 
community at this time, each with their advantages. 
2.6. Cancer Cell lines: A HeLa cell is a cell type in an immortal cell line used in 
experimental work in research field. It is the oldest and most commonly used human cell line 
(Rahbari et al., 2009). The line was derived from cervical cancer cells taken on February 8, 
1951(Scherer et al., 1951) from Henrietta Lacks. The cell line was found to be remarkably 
durable and prolific as illustrated by its contamination of many other cell lines used in research 
(Batts DW, 2010; Capes-Davis et al., 2010). 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
OBJECTIVES 
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OBJECTIVES 
1. Microarray expression analysis of tumors of epithelial, mesenchymal and  
haematopoietic origin 
 
2. Identification of overlapping sets of differentially expressed genes 
expressed in tumors of epithelial (Brain, Stomach, Cervical cancer), 
mesenchymal (Leiomyosarcoma, Liposarcoma and Myxofibrosarcoma) 
and haematopoietic origin tumours (lymphoma)  
 
3. Uncovering the genes which are exclusively expressed in epithelial 
tumors (Brain, Stomach, Cervical cancer) 
 
4. Establish a molecular signature profile for the epithelial tumors 
 
5. Experimentally validate selected sets of genes that are abnormally 
differentially expressed  
 
 
 
 
 
 
 
 
 
  
 
 
MATERIALS & METHODS 
 
 
 
11 | P a g e  
 
MATERIALS & METHODS 
4.1. Gene Expression Data: Gene Expression is the process by which information of a 
given gene is used to synthesis a functional gene product (RNA or Protein). From the 
expression of a gene we can enumerate the concentration as well as the activity of the 
respective gene. Nonstandard amounts of gene product can be correlated with different 
diseases like cancer. Gene expression data are obtained from Gene expression omnibus 
(GEO) database of National Center for Biotechnology Information (NCBI). GEO is a public 
functional genomics data repository, which provides different tools to help the user query, 
access downloadable experimental data and curated gene expression profiles. 
4.2. GEO data organisation: 
4.2.1. GEO Series (GSE): A GEO series represents a curated collection of a group of 
samples corresponding to one publication, which are biologically and statistically comparable 
records. It may contain tables describing extracted data, summery conclusion or analysis. 
Each Series record is assigned a unique and stable GEO accession number.   
4.2.2. GEO Sample (GSM): It is a sample record, which describes the conditions under 
which individual samples was handled. A sample entity must reference only one platform and 
may be include in multiple series. Each sample record is assigned a unique and stable GEO 
accession number. 
4.2.3. GEO Platform (GPL): Stores the position and corresponding feature of each probe 
(spot) such as a GenBank accession number, open reading frame (ORF) name and clone 
identifier. Each Platform record is assigned a unique and stable GEO accession number. It is 
denoted as GPLxxx. A Platform may reference many Samples that have been submitted by 
multiple submitters. In our study, all these datasets are from one platform i.e. Affymetrix 
Human Genome U133A Array [HG-U133A], platform ID: GPL96. 
          
For experimental performance, we used previously analysed datasets of different types of 
cancers with respect to normal tissue from GEO database. Three different types of cancers 
are taken for our analysis- carcinomas, sarcomas and haematopoietic cancers. In carcinomas, 
we considered Glioblastoma (Brain), Cervical and Stomach cancers; in sarcomas, 
liposarcoma, leiomyosarcoma, myxofibrosarcoma and in haematopoietic cancer, lymphoma 
for further molecular signature analysis. The gene expression or mRNA expression data 
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signifying two different criteria i.e. human normal tissues and cancerous tissues which we 
have considered for our study is given in Table 1. 
4.3. Epithelial Cancers: 
Table-1: The sources of Epithelial Cancers samples considered for analysis 
    Cancer Names                         Source Name            Organism 
              Test Control/ Normal 
Glioblastoma(Brain)  Glioblastoma 
 
Normal brain 
tissues 
     Homo sapiens 
Cervical Squamous cell  
Carcinoma 
Normal cervix 
epithelium 
     Homo sapiens 
Stomach Primary gastric tumor 
 
Normal gastric 
tissue. 
     Homo sapiens 
   
4.4. Sarcoma: 
Table-2: The source of sarcoma samples considered for analysis 
   Cancer Names                         Source Name            Organism 
             Test Control/ Normal 
Leiomyosarcoma Soft tissue sarcoma Human control 
normal fat 
 
     Homo sapiens 
Liposarcoma Soft tissue sarcoma 
 
Human Control 
normal fat 
     Homo sapiens 
Myxofibrosarcoma Soft tissue sarcoma 
 
Human control 
Normal fat 
     Homo sapiens 
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4.5. Lymphoma: 
Table-3: The source of Lymphoma samples considered for analysis 
    Cancer Names                           Source Name             Organism 
             Test Control/ Normal 
Lymphoma Burkitt’s lymphoma Lymphoblasts      Homo sapiens 
  
Table-4: GEO accession numbers of the samples taken for molecular signature analysis 
Cancer Names 
GSEs GSMs 
Test    Control Test Control 
Glioblatoma (Brain) GSE8692 GSE2361 
GSM215420 
GSM215423 
GSM215427 
GSM339554 
GSM339555 
GSM339556 
Cervical GSE9750 GSE9750 
GSM247650 
GSM247651 
GSM247652 
GSM247188 
GSM247189 
GSM247190 
Stomach GSE15456    GSE2361  
GSM44703 
GSM44703 
GSM44703 
GSM387757 
GSM387758 
GSM387759 
Leiomyosarcoma GSE21122 GSE21122 
GSM528322 
GSM528323 
GSM528324 
GSM528425 
GSM528426 
GSM528427 
Liposarcoma GSE21122 GSE21122 
GSM528402 
GSM528403 
GSM528404 
GSM528428 
GSM528429 
GSM528430 
   Myxofibrosarcoma GSE21122 GSE21122 
 GSM528348 
GSM528349 
GSM528351 
 
GSM528431 
GSM528432 
GSM528433 
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Lymphoma GSE1133 GSE1133 
GSM18891 
GSM18892 
 
GSM18889 
GSM18890 
 
 
4.6. Microarray Analysis of Gene expression Data: 
4.6.1. Retrieval of Gene expression Data: 
• Datasets selection via the NCBI Entrez data retrieval system, which is keywords 
based. 
• Triplicates: we took sample genes in triplicate to reduce the error occur during 
handling experiment, and to get the maximum correct result. 
• Datasets selection from GEO database based on our requirement. 
• GEO samples (GSM) were selected in triplicates; this was done to minimize the error 
rate. 
• Raw data are provided as supplementary file for each GEO samples at the end of the 
section. Samples are downloaded from supplementary files in .CEL format.  
• Raw files are downloaded as zip files. Files are unzipped and the raw file was 
extracted and renamed as “Test” and “Control” for easy handling while analysing in 
software. 
  4.6.2. Analysis of gene expression data: 
GeneSpring GX is a tool specifically designed for biologists that need powerful statistical   
methods to analyze expression data.  GeneSpring GX allows the user to understand the results 
of the statistical analyses in a biological context. GeneSpring GX provides the user with 
guidance through a complete analysis, providing results, fast. And it is an open-system 
platform. 
• Gene Spring GX user Interface: The display pane contains several graphical views 
of dataset as well as algorithm results. 
• The display pane is divided in to 3 parts: 
¾ The main GeneSpring GX Desktop in the center 
¾ The Project Navigation on the left 
¾ The GeneSpring GX workflow Browser and the Legend window in the right. 
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Figure 1: GeneSpring GX Layout 
 
4.6.3. Organizational Elements in GeneSpring GX: 
¾ Different experimental work in Gene Spring GX is organised in to Projects. 
¾ A project comprises one or more related experiments. 
¾ An experiment comprises Sample (Data source), interpretations (grouping of 
sample based on experimental parameters), analysis (Statistical steps ann 
associated results, typically entity lists). 
¾ Each sample is associated with a chip type or its technology and will be 
imported and used along with a technology. 
¾ An experiment comprises samples which all belong to the same technology. 
¾ Here, we comprised the entire experimental sample under Affymatrix HG-
U133A technology. 
¾ Each sample has associated with experimental parameter. 
¾ Each sample has to be given a parameter as Control and Test. 
• Experimental Grouping: It requires to adding parameter to define the grouping and 
replicates structure of the experiment. 
• Significance Analysis: Depending on the experimental groups, GeneSpring GX 
performs either T-test or ANOVA.  
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¾ Here, Sample grouping and significance based on the Normal and the Cancer 
sample with replicates was ANNOVA. 
• ANNOVA: It is used for computing p-values, type of correction and P-value 
computation type. 
¾ Here, cut off P-value is less than 0.05. 
•  Multiple testing correction algorithm used was Benjamini-Hochberg FDR. 
 
• Fold Change Analysis: Fold change analysis is used to identify genes with 
expression ratios or differences between a test and a control that are outside of a given 
cutoff or threshold. Fold change is calculated between any 2 conditions (Control Vs 
Test). The ratio between two conditions is calculated. It gives the absolute ratio of 
normalized intensities from the average intensities of the samples grouped. The 
entities satisfying the significance analysis are passed on for the fold change analysis. 
 
¾ Here, cut off value Fold change Value is more than 2.0 
• Retrieving of analyzed data: After getting the result, we saved the files by clicking 
on ‘save’ button and for data retrieving; we right clicked on the generated file and 
then export the files onto the desktop. 
• Venn Diagram: A Venn Diagram is used to show all the possible logical relation 
between a finite collection of gene entities. Generally, it reflects the union and 
intersection of entities passing the unpaired T-test values. 
¾ Here, in this experiment we got three Venn diagram using all the gene entities. 
¾ Epithelial cancers common genes Venn diagram (Brain cancer, Cervical 
cancer, Stomach cancer) 
¾ Mesenchymal cancers (Leiomyosarcoma, Liposarcoma, Myxofibrosarcoma) 
common genes Venn diagram. 
¾ Common genes between Mesenchymal, Epithelial and Hematopoietic origin 
cancers Venn diagram. 
¾ Export the genes: To export the genes exclusive to epithelial tissues, we 
selected the particular region by clicking on a particular arch of the Venn 
diagram and saved it first and then exported the file. 
• Heat Maps: The Heat Map displays the normalized signal values of the conditions in 
the active interpretation for all the entities in the active entity list. The legend window 
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displays the interpretation on which the heat map was generated. The expression 
value of each gene is mapped to a colour-intensity value. The mapping of expression 
values to intensities depicted by a colour-bar created by the range of values in the 
conditions of the interpretation. 
¾ Here, a concise Heat Map was generated by using extracted gene entities from 
Gene spring GX analysis. 
 
• Clustering: Cluster analysis is a powerful way to organize genes or entities and 
conditions in the dataset into clusters based on the similarity of their expression 
profiles. 
¾ A variety of clustering algorithms: K-Means, Hierarchical, Self Organizing Maps 
(SOM), and Principal Components Analysis (PCA) clustering. 
¾ A variety of interactive views such as the ClusterSet View, the Dendrogram View, 
the Java Tree view and the U Matrix View are provided for visualization of 
clustering results. 
¾  Hierarchical clustering: Hierarchical clustering is one of the simplest and 
widely used clustering techniques for analysis of gene expression data. The 
method follows an agglomerative approach, where the most similar expression 
profiles are joined together to form a group. These are further joined in a tree 
structure, until all data forms a single group. The dendrogram is the most innate 
view of the results of this clustering method. 
¾ Input parameters for clustering:  Clustering parameters are the entity list, the 
interpretation and the clustering algorithm. By default, the active entity list and the 
active interpretation of the experiment is selected. 
¾ Software used for Clustering: Cluster 3.0 
4.7. Cluster 3.0: Cluster 3.0 is an enhanced version of cluster, which was originally 
developed by Michel Eisen while at Stanford University. The input file format is .txt 
file.Software used for visualisation of cluster result: JAVA Tree View 
            4.8. JAVA Tree View: Java Treeview is an open-source, cross-platform modify that 
handles very large datasets well, and  with support of extensions file format that allow 
the results of additional analysis to be visualized and compared. The input file format 
is .cdt file. 
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Figure 2: Clustering Wizard: Input parameters 
 
 
  
4.8. Experimental Validation: 
4.8.1. Cell line Culture:  
• Cell line: These are the homogenous, fast growing cells which have desired 
properties. For experimental purpose cell lines were ordered from National Cancer 
Cell Science (NCCS), Pune, India.  
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• HeLa cell line was ordered. Because HeLa cells were the first human cells to grow 
well in the laboratory (Ewen Callaway, 2013)  
• Cell lines are maintained in MEM medium with 10% FBS (HIMEDIA), 1% antibody 
solution (Penstrep solution FROM HIMEDIA). 
• Subculture of cell lines: Subculture of cells required to relax the load of cells in the 
medium. The colour changes from red to orange then pale yellow indicates the 
sufficient utilization of media by cells.  
• Followed Protocol:  
¾ Remove the used media. 
¾ Washed the cell lines with PBS buffer, to take out the FBS supplement. 
¾ Trypsin EDTA was added to detach the adherent cells from the flask surface. 
¾ Equal amount of MEM media was added to neutralize the trypsin. 
¾ Then the cells were centrifuged at 1000 rpm for 5 minutes. 
¾ Trypsin and media was decanted. 
¾ 5 ml of MEM was added to cell again and mixed properly by tapping and cells 
were counted in a haemocytometer. 
¾ Finally, cell with fresh medium was incubated in CO2 incubator where level of 
CO2 maintained is 5%. 
¾ After 48-72 hours, cells are fully grown and ready for RNA isolation. 
 
4.8.2. RNA Isolation: RNA isolation is carried out using the cultured cell lines by the 
help of Qiagen RNA isolation kit (RNeasy Kit). 
            Followed protocol: 
1. A maximum of 1×107 cells were harvested as a cell pellet and the the appropriate 
volume of Buffer RLT (Lysis buffer) was added. 
2. 1 volume of 70% ethanol was added to the lysates and mixed well by pipetting. It 
should not be centrifuge.  
3. 700 µl of the sample, including any precipitation was transfered to an RNeasy Mini 
spin column placed in a 2ml collection tube (supplied). It was centrifuged for 15s at 
≥8000×g (13,000 RPM). Flow –through was discarded. 
4. Then 700 µl Buffer RW1 (wash buffer) was added to the RNeasy spin column. It was 
centrifuged for 15s at ≥8000×g (13,000 rpm). Flow –through was discarded. 
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5. 500 µl Buffer RPE (wash buffer) was then added to the RNeasy spin column. It was 
centrifuged for 15s at ≥8000×g (13,000 rpm). Flow –through was discarded. 
6. 500 µl Buffer RPE was again added to the RNeasy spin column. It was centrifuged 
for 15s at ≥8000×g (13,000 rpm). Flow –through was discarded. 
7. The RNeasy spin column was then placed in the new 1.5 ml collection tube and 30-50 
µl of RNase- free water was added directly to the spin column membrane. It was 
centrifuged for 15s at ≥8000×g (13,000 rpm) to elude the RNA. 
8. Using Nanodrop (Eppendorf) the purity and quantity of RNA yield is checked by 
taking only 1-2µl of the sample. 
 
4.8.3.   cDNA Synthesis: 
cDNA synthesis was carried out using SuperScript First-Strand Synthesis System for RT-
PCR by Invitrogen using oligo dT primers. 
The steps in cDNA synthesis: 
1. Each component of the kit was mixed and briefly centrifuge before use. 
2. For each reaction, the following components were combined in a sterile 0.2 or 0.5ml 
tube. 
 
3. The RNA/primer mixture was incubated at 65·c for 5 minutes and then placed on ice 
for at least 1 minute.  
4. In a separation tube, the following 2X reaction mix was prepared, by adding each 
component in the indicated order. 
 
 
Components 
 Amount 
RNA (2µg) 
 5 µl 
10 mM dNTP mix 
 1 µl 
Primer (0.5µg/µl oligo (dT)12-18) 1µl 
DEPC treated water                                  10µl 
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Components 
 1RXn 10 RXnS 
10X RT buffer 
 2 µl 20 µl 
25mM Mgcl2 
 4 µl 40 µl 
0.1M DTT 
 2 µl 20 µl 
RNase out TM (400/ µl) 
 1 µl 10µl 
 
5. 9µl of the 2X reaction mixture was added to each RNA/primer mixture from step 3 
and mixed gently and collect by briefly centrifugation. 
6. It was incubated at 42·c for 2 minutes. 
7. 1µl of super scriptTM II RT was then added to each tube. 
8. Incubated at 42·c for 50 minutes. 
9. Then, terminated the reaction at 70·c for 15 minutes. Chilled on ice. 
10. The reaction was collected by brief centrifugation and 1µl of RNase H was added to each tube 
and incubated for 20 minutes at 37·c. 
11. Then, the reaction is stored at -20·c or used for PCR immediately.  
 
4.8.3. qRT PCR: 
This protocol describes the detailed experimental procedure for real-time RT-PCR 
using SYBR Green. The procedure begins with reverse transcription of total RNA. 
The cDNA is then used as template for real-time PCR with gene specific primers. 
Materials required:  
• Oligonucleotide Primers: Gene specific primers are retrieved from primer bank. These 
primers are ordered from the SIGMA Genosys.  
• cDNA.  
• SYBR Green PCR master mix. 
• White optical tube and cap strips. 
• RT-PCR (Eppendorf). 
 
1. PRIMERS: 
Control gene: β- Actin (Housekeeping Gene) 
            Test genes: SERPINA3, SH3GL3 
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2.  Primer Concentration: (Forward & Reverse) 
            Stock: 100µM 
            Working Concentration: 10µM 
            Primer Concentration in experiment: 500nM 
            For 2 genes (3 replicates each): 70µl solution required including primers. 
            Forward Primer: 3.5 µl 
            Reverse Primer: 3.5 µl 
3. Fluorescent probe: SYBR Green mix- SYBR green, dNTP, Mg2+ 
SYBR Green concentration in experiment: 35µl (1X) 
4. cDNA diluted to 1:20 ratio: 40 µl prepared. 
Required cDNA: 28 µl 
5. Oligonucleotide Primers:   
 
 
             Table-5: Primer sequence of Control and Test genes 
 
 
 
 
 
 
 
                          
  Table-6: Cycles temperature in qRT PCR 
STAGE TEMPERATURE (°C) TIME CYCLE 
Stage 1 95 20 sec 1 
 
Stage 2 
95 
55 
68 
15 sec 
15 sec 
20 sec 
 
40 
 
Stage 3 
95 
60 
95 
15 sec 
15 sec 
15 sec 
 
1 
 
                                       
 
Oligo Name 5'<-----Sequence--->3' 
 
Lenght 
SERPINA3 F GATCGGGCATCACCTGAAAAA 21 
SERPINA3 R TCGTCTGGTATCTTACCTACTCG 23 
SH3GL3 F CCTGAAGGCCCCTGATAAGAA 21 
SH3GL3 R GCTGGACTGATTGAGGGTGC 20 
β-Actin F CATGTACGTTGCTATCCAGGC 21 
β-Actin R CTCCTTAATGTCACGCACGAT 21 
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                               Figure 3. Cycle temperature and time for qRT-PCR 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
RESULTS AND DISCUSSIONS 
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RESULTS & DISCUSSIONS 
5.1.  Microarray analysis: 
• From microarray analysis using GeneSpring GX, we obtained 348 differentially 
expressed genes expressed common to cancers of epithelial origin, i.e. brain, stomach, 
cervical cancer. 
  
Figure 4. Venn diagram representing the common genes expressed in epithelial 
origin cancer (Brain, Stomach, Cervical cancer) 
 
Figure 5. Venn diagram representing the common genes expressed in 
mesenchymal origin cancer 
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• From mesenchymal tumor (Leiomyosarcoma, Liposarcoma and Myxofibrosarcoma) , 
we obtained 545 common genes, which has   mesenchymal origin. 
 
• By comparing common genes differentially expressed in all three types of cancer of 
different origin (epithelial, mesenchymal and lymphoma), we got 201 genes that are 
exclusively differentially expressed in cancers of epithelial origin. 
 
Figure 6 : Venn diagram representing the common genes & exclusive sets of genes 
between Epithelial, mesenchymal and Lymphoma origin cancer  
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5.2. Clustering:   
 
Figure 7 : Heat Map of microarray data of epithelial origin cancers 
 
5.3. Gene list analysis: 
• According to our objectives, we selected exclusive epithelial origin cancer related 
genes for further molecular signature analysis. The exclusive sets of epithelial origin 
cancer contained 201 numbers of genes, which are exclusively present in Brain, 
Cervical and stomach cancer. 
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Table 7: Exclusive set of genes in epithelial origin tumors (Stomach, Cervical, Brain 
cancer) 
Gene 
Symbol 
Regulation 
in Stomach 
cancer 
Fold change in 
stomach 
cancer 
Regulation 
in cervical 
cancer 
Fold 
change in 
cervical 
cancer 
Regulation 
in brain 
cancer 
Fold change 
in brain 
cancer 
PSMB2  Down  2.2474647  down  2.591263  Down  2.153261 
ATP6V1G2   Down  2.1245968  down  2.277777  Down  2.827335 
CD24  Down  2.1388943  up  2.543346  Down  2.133525 
MAFF  Down  3.7758126  up  6.990386  Down  3.791928 
MSN  Down  2.3790982  down  2.603572  Down  4.95187 
MLEC  Down  2.2913814  down  2.465684  Down  4.08609 
PFN1  Down  2.0546515  down  2.540145  Down  4.025861 
SPARC  Down  7.3933825  down  4.089357  Down  8.2469 
DNAJB1  Down  2.2949274  up  2.43908  Down  2.361121 
LITAF  Down  3.858532  down  2.070647  Down  2.053864 
LAMC1  Down  2.2272682  down  2.6912  Down  11.05916 
ANXA5  Down  3.4218462  down  2.419475  Down  7.230515 
SCD  Down  7.347266  down  4.224112  Up  2.400863 
CTSB  Down  3.0131385  down  2.760871  Down  2.126846 
CTSB  Down  4.0379577  down  2.283448  Down  2.46261 
LGALS3BP  Down  2.1090496  down  2.353593  Down  4.16987 
DEK  Down  2.0504317  down  3.16221  Down  2.067486 
PPIB  Down  2.4568062  down  5.211479  Down  3.167322 
SERPING1  Down  4.608875  down  3.298965  Down  3.461534 
PAICS  Down  3.2486641  down  2.143968  Down  3.642463 
PFKP  Down  3.1139922  down  2.45083  Up  3.131392 
STOM  Down  3.5062802  down  3.729752  Down  2.725554 
RCN1  Down  3.240057  down  6.09659  Down  3.128266 
MMP2  Down  2.6291802  down  2.191986  Down  3.399188 
CBX3  Down  3.124692  down  2.49818  Down  2.044873 
HLA‐DPB1  Down  2.130417  down  2.721022  Down  15.79708 
IDH1  Down  2.2729692  down  2.245146  Down  6.186771 
RRBP1  Up  2.1497543  down  2.12737  Down  2.376985 
ARHGDIB  Down  2.4134653  down  2.098466  Down  5.663301 
SOX4  Down  2.8947997  down  2.18217  Down  20.64291 
COL6A3  Down  7.0182147  down  3.064116  Down  2.788027 
JUN  Up  2.0348654  up  2.773805  Down  3.680503 
RRM1  Down  2.6544075  down  2.407301  Down  2.748774 
G3BP1  Down  3.7455091  down  2.078785  Down  2.401074 
LAMB1  Down  3.338808  down  2.26632  Down  3.452669 
TGFBI  down  3.7333894  down  3.738732  Down  8.903104 
MCM3  down  2.7512023  down  3.999191  Down  3.881331 
IFITM1  down  3.9529696  down  2.662751  Down  2.002034 
IER3  down  2.0629313  up  3.947531  Down  2.324432 
UBE2L6  down  2.033642  down  2.695916  Down  2.32301 
TIMP1  down  5.8077855  down  2.526132  Down  14.71475 
LAPTM5  down  2.589336  down  4.104724  Down  8.402963 
SGK1  up  2.7926662  up  2.311896  Down  2.225214 
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CD14  down  2.0339742  down  4.395381  Down  18.04268 
LUM  down  2.8608117  down  4.953169  Down  4.807593 
MTHFD2  down  2.0601537  down  7.606896  Down  10.24751 
AEBP1  down  3.5108612  down  3.393021  Down  2.498676 
LBR  down  2.3810449  down  2.657699  Down  6.953003 
LPCAT1  down  2.7648711  down  4.416288  Down  2.879076 
 
 
• From 201 genes, we shortlisted 10 genes on the basis of standard fold change value 
(10 fold change) and biomarker potential in different epithelial carcinoma. 
• From shortlisted 10 genes, two genes are taken for experimental validation. 
• Selected genes: SERPINA3, SH3GL3  
 
Table 8: Genes shortlisted for further analysis & validation 
 
 
 
 
 
 
 
 
 
 
 
 
                                 
SERPINA3 (NCBI, Gene ID- 12): 
• SERPINA3 has different aliases, Serpin peptidase inhibitor, clade4 
(alpha1antiproteinase, antitrypsin member3) or Alpha-1 antichymotrypsin. Serine or 
cystein proteinase inhibitor, clade4, mem-3. It’s a member of the serine protease 
inhibitor class. It comes under cell-growth inhibiting gene. It has plasma protein 
inhibiting capacity. Polymorphism in this gene leads to protease targeting. It is tissue 
specific. Variation causes Alzheimer’s disease and deficiency causes liver disease. 
Mutation in SERPINA3 causes Parkinson’s disease & chronic pulmonary disease. 
Alpha-1 anticymotrypsin is an acute phase protein, which level increases in acute & 
Gene names Regulation 
CD14 Down 
COLIA1 Down 
SOX4 Down 
MVP Down 
CTSL2 Down 
SERPINA3 Down 
GULP Up 
NEBL Up 
SH3GL3 Up 
FXYD Up 
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chronic inflammation. It is related to JAK STAT pathways. The A/T polymorphism in 
SERPINA3 gene influences expression of this protein, while T allele was strongly 
down regulated; it induced the high level of cathepsin activit. 
  
SH3GL3 (NCBI,Gene ID-6457):  
• SH3GL3 has different aliases domain GRB2-like protein 3.This gene is implicated in 
endocytosis. Present in cytoplasm as a peripheral membrane protein. Protein of 
SH3GL3 is endophilin-A3 contains 347 amino acids, weight is 39285 Da. No specific 
pathways. 
5.4 Experimental validation: 
 
           RNA isolation: 
• 260/280 Ratio: This ratio indicates the absorbance of DNA and RNA at 260 nm and 
280 nm, which is used to assess the purity of DNA and RNA. A ratio is expected 
approximately 1.8 and generally accepted as “pure” for DNA; a ratio of 
approximately 2.0 is generally accepted as “pure” for RNA. If the ratio is significantly 
lower in either case, it may indicate the presence of protein, phenol or other 
contaminants that absorb strongly at or near 280 nm.  
• 260/230 Ratio: This ratio is used as a secondary measure of nucleic acid purity. The 
260/230 values for “pure” nucleic acid are often higher than the respective 260/280 
values. Expected 260/230 values are normally in the range of 2.0-2.2. If the ratio is 
significantly lower than expected, it may indicate the presence of contaminants which 
absorb at 230 nm.  
• Here, we got following results of two samples; Sample1 has perfect ratio absorbance 
in 260nm and 280 nm wavelengths where Sample2 has less value. 
       
• Sample1 = 500.6 µg/ml 
At (260/280) ratio = 1.99 
At (260/230) ratio = 2.01  
 
• Sample 2 = 125.2 µg/ml 
At (260/280) ratio = 1.54 
At (260/230) ratio = 1.10 
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qRT-PCR :  
• Generally qRT-PCR melting curve analysis used to quantify nucleic acid, mutation 
detection and for genotype analysis. 
• From qRT PCR analysis of SERPINA3, we got fine melting temperature curve of 
SERPINA3 in comparison with control gene, β-actin. Melting temperature of 
SERPINA3 is 80·c. Samples of gene taken in triplicates. Three picks of SERPINA3 
positioned at one place. Relative quantification with respect to control gene 
representing, high expression of SERPINA3.  
 
 
Figure 8: Relative quantification result of SERPINA3 with respect to control gene, 
 β-  Actin in qRT PCR analysis 
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        Figure 9: Relative expression of SERPINA3 and SH3GL3 with respect to control 
• From the relative gene expression study of SERPINA3 and SH3GL3, it is cleared that 
both are up regulated in Hela cell line.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 10
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CONCLUSION 
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CONCLUSION 
By studying the gene expression of brain, stomach, cervical cancer; we are able to 
identify a set of genes that are exclusively expressed in cancers of epithelial origin 
that can be used as molecular signature for all types of cancers that originated in 
epithelial tissues. By using these molecular gene expression signatures, we will be 
able to diagnose tumors for their origin where EMT has occurred. Further screening 
of 201 exclusive set of genes gave rise to 10 genes which are proposed to play a 
significant role in cancers of epithelial origin, out of which 2 genes (SERPINA3, 
SH3GL3) were experimentally validated in HeLA cancer cell lines by RT-PCR 
method for their expression.     
qRT-PCR established that these two genes are showing their up regulation in 
comparison to control gene, β-actin. β-actin is a housekeeping gene, it expressed in all 
cells of an organism under normal and patho-physiological conditions. Even though in 
Microarray data analysis SERPINA3 to be down regulated (Kloth et. al., 2008) and 
SH3GLE3 has up regulated expression (Fang et. al., 2012 and Nguyen et. al., 2007), 
but qRT PCR showed  up regulation which gave the idea that there might be some 
error in microarray data analysis or during validation. To know  its regulation further 
well in epithelial tumors we will have to check its expression in normal cell lines too.  
Several interesting candidate genes can have potential as therapeutic targets 
that are obtained from our present analysis. Validation of gene expression signatures 
in larger series needs to be performed to improve the understanding of the metastatic 
process of epithelial cancer further. SERPINA3 is a serine protease inhibitor (Serpins) 
which belongs to the Serpins superfamily with inhibitory activity. SERPINA3 has 
versatile role and in associated with inflammatory reaction in malignant melanoma 
and gastric cancer. It’s a potential biomarker in colorectal cancer (CRC) progression 
(Kloth et. al., 2008). We considered that the up regulation expression of SERPINA3 
may be considered as signature in epithelial carcinoma like brain, stomach, cervical 
cancer. Furthermore, the second gene SH3GL3 is associated with colorectal cancer 
and is a potential biomarker (Fang et. al., 2012 and Nguyen et. al., 2007) and same 
can be assumed for cancers of epithelial origin, but needs further validation. For 
establishing our gene-expression signature that distinguishes epithelial cancer from 
mesenchymal as well as hematopoietic cancer with high confidence, further validation 
of many differentially expressed genes are needed.  
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